U.S. FDA accepts new drug application for triple combination tablet for adults with type 2 diabetes

Eli Lilly

4 June 2019 - The U.S. FDA has accepted the new drug application for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release for the treatment of adults with type 2 diabetes, Boehringer Ingelheim and Eli Lilly have announced.

The application is based on two randomised open-label trials that assessed the bioequivalence of empagliflozin, linagliptin and metformin XR investigational fixed-dose combination tablets and their individual components in healthy adults. Boehringer Ingelheim and Lilly plan to present results from the trials at a medical congress later this year.

Read Eli Lilly press release

Michael Wonder

Posted by:

Michael Wonder